RxDoctor Payments Data

Nasser Tehrani, MD

Interventional Cardiology · Perry, GANPI 1831185388

Payments from drug & device makers

$9,634in general payments, 2019–2025

Across 174 payments — averaging $55.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Medical Device Business Services, Inc.$817
  • Cardiovascular Systems Inc.$776
  • Philips North America LLC$708
  • Merck$374
  • Shockwave Medical, Inc$297
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$5,38956%
  • Food & beverage$4,23144%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,634 in reported general payments places this provider in the 50th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$792,337
Medicare patients
992
Services billed
13,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban596$597,474
EntrestoSacubitril/Valsartan274$317,904
Repatha SureclickEvolocumab225$187,697
Repatha SyringeEvolocumab80$87,625
FarxigaDapagliflozin Propanediol84$85,130
BrilintaTicagrelor110$84,098
OzempicSemaglutide58$80,175
VerquvoVericiguat86$77,221
XareltoRivaroxaban83$76,190
Ranolazine ErRanolazine612$66,164
NexlizetBempedoic Acid/Ezetimibe58$44,978
Ezetimibe1,117$15,989
Praluent PenAlirocumab17$13,628
ClopidogrelClopidogrel Bisulfate1,083$11,038
Atorvastatin Calcium1,050$9,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$597,474596 claims
NovartisEntresto$108$317,904274 claims
AstraZenecaFarxiga, Brilinta$110$169,228194 claims
Novo NordiskOzempic$127$80,17558 claims
MerckVerquvo$374$77,22186 claims
Johnson & JohnsonXarelto$67$76,19083 claims
Esperion Therapeutics, Inc.Nexlizet$226$44,97858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Perry

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →